Short answer: no. The FDA label for Ozempic says a pen must never be shared between people, even if the needle is changed. The Mounjaro and Zepbound KwikPen labels say the same thing, and so do insulin pen labels like Lantus SoloStar and Humalog KwikPen. The reason is blood-borne infection. Small amounts of blood and skin cells can get back into a pen during an injection, and a fresh needle does nothing about what is already inside the cartridge.
This question came up a lot in our Instagram comments this week, usually in one of three forms: "Does a used pen really hold blood?", "Is it fine if we each use our own needle?" and "Does the same go for insulin pens?" Here is what the labels and the research say, in plain words, with sources linked inline.
What the Ozempic label says
The Ozempic prescribing information has a full warning section titled "Never Share an OZEMPIC Pen Between Patients" (section 5.4). It says Ozempic pens must never be shared between patients, even if the needle is changed, because pen-sharing poses a risk of passing on blood-borne pathogens (Ozempic label, DailyMed).
The patient Medication Guide puts it even more directly. It tells you not to share your Ozempic pen with other people, even with a new needle, because you may give someone a serious infection or get one from them. The carton itself is printed "For Single Patient Use Only."
Each Ozempic pen holds several weekly doses: 4 doses at the 1 mg and 2 mg strengths, for example. That is exactly why sharing is tempting. One pen looks like it could cover two people for two weeks. The label is written to close that door.
What the Mounjaro and Zepbound labels say
Mounjaro and Zepbound (both tirzepatide) come in more than one form, and the rule depends on which one you have.
- KwikPen (4 weekly doses per pen): Both labels have a warning section, 5.10, saying never share a KwikPen between patients, even if the pen needle is changed, because of the risk of blood-borne pathogens (Mounjaro label, DailyMed; Zepbound label, DailyMed).
- Single-dose pens: These hold one dose and are thrown away after use, so there is nothing left to share.
- Vials: The instructions say to use a new syringe and needle for every injection and never to reuse or share syringes or needles, because of the same infection risk.
The Mounjaro label also says to throw away a KwikPen or multi-dose vial after 4 weekly doses or 30 days, even if there is medicine left in it. Leftover liquid at the end is not a spare dose for someone else.
Does a used pen really hold blood?
It can. The needle passes through your skin into the tissue underneath, and it stays connected to the cartridge while you inject and hold. Anything that gets into the needle can reach the medicine. You can't see it, and it doesn't happen with every injection, but researchers have looked for it inside used pens and found it.
- Le Floch and colleagues, 1998: A nurse gave an injection with each of 120 patients' own insulin pens, then the needle and the cartridge were checked under a microscope. Biological material, mostly skin and other cells, was found in 30% of needles and 58% of cartridges (PubMed 9727898). The authors' conclusion was that pens and cartridges must be strictly for one person.
- Herdman and colleagues, 2013: This study tested the insulin inside 125 used hospital pens. Seven (5.6%) were positive: six had cells, including one red blood cell, and one had free hemoglobin, a marker of blood (PubMed 23820462). The authors wrote that this creates a potential path for infection between patients even when a new needle is used for each person.
One more recent study, funded by Novo Nordisk, found no biological signal in most used needles (95%) and cartridges (86%) and focused on infection risk for the person using their own pen (PubMed 35460122). That fits the picture: contamination is uncommon in any single pen, but it is not zero, and you have no way of knowing which pen is the one that has it. These are research findings in insulin pens, not Ozempic pens specifically, but the pen designs work the same way, which is why the warning is the same.
Does the same go for insulin pens?
Yes, and insulin pens are where the rule started. The Lantus SoloStar label opens its warnings with section 5.1: never share a SoloStar pen between patients, even if the needle is changed (Lantus label, DailyMed). The Humalog label says the same about prefilled pens, cartridges and reusable pens that take Lilly cartridges (Humalog label, DailyMed).
On February 25, 2015, the FDA issued a Drug Safety Communication requiring a "For single patient use only" warning on multi-dose pens for insulin and other injectable diabetes medicines. The federal patient-safety summary of that notice says sharing these pens has been linked to health care-associated infections (AHRQ PSNet summary of the FDA notice).
The CDC's injection safety guidance says each insulin pen should be assigned to one person and labeled, and that pens must never be used for more than one patient because blood may be present in the pen after use (CDC injection safety).
"But it's my partner, not a stranger"
The labels don't make an exception for family, a partner or a friend. Blood-borne infections such as hepatitis B, hepatitis C and HIV don't always cause symptoms, so "we're both healthy" is not something either person can know for sure without testing. The rule is simple on purpose: one pen, one person, every time.
Cost is usually the real reason people ask. If a pen is the problem, the better move is to talk to your prescriber or pharmacist about the form, strength or supply that fits you, not to split a pen.
What if you already shared a pen?
Don't panic, and don't ignore it. Stop sharing right away and tell your doctor or pharmacist what happened and when. They can decide whether any blood tests make sense for you. If you used someone else's pen to take a dose, also tell them which dose and strength, since it may affect your own schedule.
Habits that make sharing impossible by accident
- One pen per person, labeled. If two people in your home use the same drug, write names on the pens or keep them in separate boxes. Same-colored pens are easy to mix up in a fridge door.
- New needle every time. The Ozempic instructions say this lowers the risk of contamination, infection, leakage and blocked needles that lead to the wrong dose.
- Bin needles and empty pens right away. The Ozempic instructions say to put used pens and needles straight into an FDA-cleared sharps container.
- Know which pen you're on. Keep a note of when you opened each pen and how many doses are left. Ozempic pens can be kept for 56 days after first use; Mounjaro and Zepbound KwikPens for 30 days or 4 doses.
For the step-by-step on handling a pen correctly, see our guide to using an injection pen. For drug-specific details, there are overview pages for Ozempic and Mounjaro. Dose Track can also log each pen you open and the doses you take from it, so you always know which pen is yours and how much is left.
The bottom line
A new needle protects the next person from your needle, not from your pen. Ozempic, Mounjaro KwikPen, Zepbound KwikPen and insulin pens all carry the same FDA label warning: never share a pen between people, even with a fresh needle. Research has found cells and traces of blood inside used pens. If you have questions about your own pens or doses, ask your prescriber or pharmacist.
Sources
- Ozempic (semaglutide) injection prescribing information, Medication Guide and Instructions for Use, DailyMed setid adec4fd2: sections 5.4, 16, 17.
- Mounjaro (tirzepatide) prescribing information and Instructions for Use, DailyMed setid d2d7da5d: sections 5.10, 16.
- Zepbound (tirzepatide) prescribing information and Instructions for Use, DailyMed setid 487cd7e7: section 5.10.
- Lantus prescribing information, DailyMed setid d5e07a0c: section 5.1. Humalog prescribing information, DailyMed setid c8ecbd7a: section 5.1.
- FDA Drug Safety Communication, February 25, 2015, as summarized by AHRQ PSNet.
- CDC, Injection Safety: infection control guidance on insulin pens.
- Le Floch JP et al. Diabetes Care 1998 (PubMed 9727898). Herdman ML et al. Am J Health Syst Pharm 2013 (PubMed 23820462). Wareham-Mathiassen S et al. APMIS 2022 (PubMed 35460122).
This article is general information from FDA labels and published research. It is not medical advice. Talk to your prescriber or pharmacist about your own treatment.

